SCHEMBL30225261

SCHEMBL30225261

O=C1Cc2cnccc2CN1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.42
CHRNA4 P43681 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
PDE3B Q13370 5/20 0.39
PDE3A Q14432 5/20 0.39
CYP11B1 P15538 2/20 0.37
CYP11B2 P19099 2/20 0.37
CYP1A2 P05177 1/20 0.37
DAO P14920 2/20 0.36
TDP2 O95551 2/20 0.36
TIPARP Q7Z3E1 2/20 0.36
MKNK2 Q9HBH9 2/20 0.35
KDM4A O75164 1/20 0.34
KDM4B O94953 1/20 0.34
KDM5C P41229 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
KDM5B Q9UGL1 1/20 0.34
KDM3A Q9Y4C1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23975908 1.00 CHRNB2 (0.42) CHRNB2CHRNA4SIGMAR1PDE3BPDE3A
SCHEMBL17376995 0.92 CHRNB2 (0.42) CHRNB2CHRNA4SIGMAR1PDE3BPDE3A
SCHEMBL89023 0.74 ALOX15 (0.56) CYP1A2TDP2
SCHEMBL7343370 0.74 CYP1A2 (0.50) CHRNB2CHRNA4SIGMAR1PDE3BPDE3A
SCHEMBL8419080 0.73 SIGMAR1 (0.56) CHRNB2CHRNA4SIGMAR1CYP1A2
SCHEMBL29526300 0.72 PDE3B (0.54) PDE3BPDE3ACYP11B1CYP11B2CYP1A2
SCHEMBL658301 0.72 PDE3B (0.59) PDE3BPDE3ACYP11B1CYP11B2CYP1A2
SCHEMBL477609 0.72 PDE3B (0.54) PDE3BPDE3ACYP11B1CYP11B2CYP1A2
SCHEMBL19152529 0.72 PDE3B (0.34) PDE3BPDE3ACYP11B1CYP11B2CYP1A2
SCHEMBL1118591 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4142732-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS Global Blood Therapeutics, Inc. (US) 2023-03-08 EP disclosed
EP-4143178-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS Global Blood Therapeutics, Inc. (US) 2023-03-08 EP disclosed